Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DWJ1622 in Healthy Volunteers
NCT07260851Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enavogliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours and Area Under the Plasma Concentration-Time Curve to the Last Measurable Concentration at 72 hours. Started Nov 2025; status: recruiting.
02
Drugs
enavogliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07260851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260851.